Biospecimens are recognized as critical components of biomedical research, from basic studies to clinical trials and epidemiologic investigations. Biorepositories have existed in various forms for more than 150 years, from early small collections in pathology laboratories to modern automated facilities managing millions of samples. As collaborative science has developed, it has been recognized that biospecimens must be of consistent quality. Recent years have seen a proliferation of best practices and the recognition of the field of "biospecimen science." The future of this field will depend on the development of more evidence-based practices in both the research and clinical settings. As the field matures, educating a new generation of biospecimen/biobanking scientists will be an important need. Cancer Epidemiol Biomarkers Prev; 21(2); 253-5. Ó2012 AACR.
Good Biospecimens Are Hard to Find
This editorial could also have been entitled "Biobanking 1 : A Tricky Endeavor" but that was already used for the biospecimen session at the AACR conference on The Science of Cancer Health Disparities held in September 2011 (1) . Biospecimens (blood, urine, tissue-fresh-frozen, paraffin-embedded, saliva, various cells) have been organized into formal collections in the United States. for more than 150 years, starting in the Civil War era with the pathology specimens that resulted in the largest collection in the United States at the Armed Forces Institute of Pathology (2) . Many smaller collections exist in pathology laboratories and clinics. And larger population-based collections are managed at multiple academic and clinical centers and at the NIH (Bethesda, MD; ref. 2) .
Standards Were Late in Coming
Given the millions of samples collected for clinical and research purposes, for most of the history of biobanking, there has been a serious lack of attention to control the quality and consistency of collection, processing, and storage of biospecimens. A brief list of high-profile biospecimen-related problem areas include the following: (i) high rates of false positives and false negatives in HER2 analyses traced to inconsistent biospecimen handling among laboratories (3); (ii) invalid results from early clinical proteomic and other biomarker studies related to differences in biospecimen handling protocols (4); and (iii) more recently, inadequate quality of tissue samples for The Cancer Genome Atlas pilot study (5) . As these and other specimen-related issues have emerged over the past 10 years, efforts have been under way to develop best practices to guide biobank managers and investigators who rely on biospecimens for their research (6) . In addition to technical approaches to biospecimen collection, processing, and storage, best practices also include guidance on important overarching issues such as quality management, ethical and regulatory requirements, and information systems management (7) . The emerging ethical, regulatory, and societal issues facing biobanks are the most difficult to coordinate and standardize, including issues such as the return of research results, pediatric consent, and the accessibility of specimens and data (8) .
Although "best practices" have been increasingly adopted, it has to be noted that they are generally based on empirical observations, that is, not evidence-based. There is still a lot that is not known about optimal biospecimen practices. For example, for many blood analyses, data concerning the effects of multiple freeze-thaw cycles and other preanalytic variables are difficult to find. Recently, the National Cancer Institute (NCI) and other programs have developed biospecimen research initiatives to systematically study such variables and produce evidencebased standards (9, 10).
The Issues Are Global
Many research initiatives are now international in nature. This presents special problems for studies involving biospecimens. Although as noted there is a proliferation of best practices, there is little international coordination of biospecimen standards, both from the operational and ethical/legal perspectives (6) . As a result, investigators sharing samples and otherwise collaborating across borders must take care that quality standards are established prior to specimen collection. In addition, there are many political and regulatory obstacles to send specimens outside of various countries. However, a number of productive biospecimen networks have been developed, especially in Europe, Australia, and Asia that have been successful in establishing standards and sustainable business models (11) .
Evolution of Biospecimen Types
Traditionally, the major division among biorepository types has been between tissue and blood samples collected in surgical and pathology suites for clinical research applications and those collected for population-based studies, generally blood, urine, and saliva samples. As new technologies such as tissue and expression microarrays (12) have evolved, so have the specimen types and the methods to collect them changed (13) . More recently, methods have been developed to isolate and study circulating tumor cells with highresolution imaging techniques (14) . A major factor affecting these trends is the availability of new analytic technologies. As smaller and smaller samples are needed for analyses, collection methodologies continue to evolve as well. For example, where microgram quantities of DNA were needed for early genomic analyses, nanogram quantities are now sufficient and DNA from saliva is increasingly used (15) . And methods such as laser capture microdissection provide additional tools for specialized analytic applications (16).
Technologies and Economics
As sample types have evolved, so have the technologies necessary to process and store the increasing variety of biospecimens. One key to this process is the increasing recognition that biospecimen management is an expensive proposition. A large epidemiologic biorepository that processes and houses millions of samples each year can cost millions of dollars to construct and operate. The requirements for such a large facility include sophisticated equipment monitoring and alarm systems; back-up generators for power failures; quality management protocols; and well-developed procedures for processing, storing, and shipping samples (17) . For studies where extra aliquots of samples are maintained in freezers whereas others are undergoing analyses, storage costs alone can be $10,000 or more on an annual basis.
Economic factors, along with the need for other spacesaving and efficiency measures, have led to the development of new technologies. Among these are automated sample aliquoting and nucleic acid extraction instruments that have greatly increased the productivity of biorepositories (18, 19) . Additional efforts have gone into developing alternative storage models. Although the Centers for Disease Control and Prevention has been collecting and analyzing newborn blood spot cards for many years, newer dry-state techniques, for example, from Biomatrica (20) and GenVault (21) have led to additional advances, reducing costs while maintaining blood, nucleic acids, proteins, and saliva samples at ambient temperatures.
The Molecular Epidemiology Perspective
Biospecimens for molecular epidemiology studies have continued to focus on genetics and genomics (i.e., genome-wide association studies, high-density sequencing, and exome sequencing) in the last few years and this trend will continue (22, 23) . But the need to measure metabolites, such as estrogens/androgens (24), smallmolecule proteins and pathways, large proteins, and even components of the microbiome (25), has expanded. The increasing need for blood and blood products, tissues, and other body fluids is driven by new analytic tests. There is still a need to understand optimal ways to process and store specimens for these tests and future applications and methods to store specimens in more cost-effective, energy-efficient ways. These needs include new automation where appropriate, initially in the processing, handling, and testing areas as thousands of samples often need to be analyzed.
In terms of molecular epidemiologic study initiatives, the genetic focus with an attempt to identify gene-environment interactions has necessitated larger and larger sample sizes. With this in mind, investigators are pooling samples from a variety of international study sites (26) . This globalization of investigations introduces the hazard of variable collection, processing and storage conditions among sample sets, and the accompanying chance that assay results will differ due to these varied conditions. As is the case for clinical studies, evidence-based protocols that are widely recognized and adopted are needed to minimize the problems associated with comparison of assay results across collections.
For additional information, see the Focus: Biomarkers and Biospecimens section published in the April 2010 issue of Cancer Epidemiology, Biomarkers, and Prevention (19:901-1015).
Degree Programs and Beyond
As was the case in the development of molecular epidemiology 2 decades ago, where training of epidemiologists in laboratory science had to be integrated and developed over time, biospecimen science has evolved informally and "on the job" under the leadership of experts in pathology, epidemiology, clinical chemistry, biochemistry, molecular biology, and related disciplines. Until now, there has been no formal training in the new field of biospecimen science. Recently, a new masters degree program in biobank management was initiated in France (28) and the formal accreditation and certification of biorepositories by the U.S. College of American Pathologists (29) . As degree programs, evidence-based practices, proficiency testing, accreditation programs, and biospecimen research and publications grow and expand in scope, it is obvious that the field of biobanking has evolved from the earlier view that simply embedding or freezing biospecimens with no consideration of preanalytic variables was sufficient, into a true scientific discipline. But, it is still a tricky endeavor.
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